MISOPROSTOL AS PREVENTION OF POSTPARTUM HEMORRHAGE: A TEN YEARS SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/cd8zg406Keywords:
Misoprostol, postpartum hemorrhage (PPH), uterotonicAbstract
Background: Postpartum Haemorrhage (PPH) is commonly defined as a blood loss of 500 ml or more within 24 hours after birth. PPH is the leading cause of maternal mortality in low-income countries and the primary cause of nearly one quarter of all maternal deaths globally.
The aim: This study aims to show about misoprostol as prevention of postpartum hemorrhage.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 23 articles, whereas the results of our search on SagePub brought up 39 articles. The results of the search conducted for the last year of 2014 yielded a total 13 articles for PubMed and 27 articles for SagePub. The result from title screening, a total 5 articles for PubMed and 14 articles for SagePub. In the end, we compiled a total of 10 papers. We included five research that met the criteria.
Conclusion: Other injectable uterotonics and misoprostol are recommended as alternatives for the prevention of PPH in settings where oxytocin is unavailable.
References
Haver J, Ansari N, Zainullah P, Kim YM, Tappis H. Misoprostol for Prevention of Postpartum Hemorrhage at Home Birth in Afghanistan: Program Expansion Experience. J Midwifery Women’s Heal. 2016;61(2):196–202.
Durham J, Phengsavanh A, Sychareun V, Hose I, Vongxay V, Xaysomphou D, et al. Misoprostol for the prevention of postpartum hemorrhage during home births in rural Lao PDR: Establishing a pilot program for community distribution. Int J Womens Health. 2018;10:215–27.
Uncu Y, Karahasan M, Uyaniklar, Uncu G. Prophylactic misoprostol for the prevention of postpartum hemorrhage: A randomized controlled trial. Eur Rev Med Pharmacol Sci. 2015;19(1):15–22.
Rajaei M, Karimi S, Shahboodaghi Z, Mahboobi H, Khorgoei T, Rajaei F. Safety and efficacy of misoprostol versus oxytocin for the prevention of postpartum hemorrhage. J Pregnancy. 2014;2014.
Prata N, Weidert K. Efficacy of misoprostol for the treatment of postpartum hemorrhage: Current knowledge and implications for health care planning. Int J Womens Health. 2016;8:341–9.
Numfor E, Fobellah NN, Tochie JN, Njim T, Ndesso SA. Oxytocin Versus Misoprostol Plus Oxytocin in the Prevention of Postpartum Hemorrhage at a Semi-Urban Hospital in sub-Saharan Africa: A Retrospective Cohort Study. Int J Matern Child Heal AIDS. 2020;9(3):287–96.
Koch DM, Rattmann YD. Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach. Einstein (Sao Paulo). 2020;18:eAO5029.
Abbas DF, Mirzazada S, Durocher J, Pamiri S, Byrne ME, Winikoff B. Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: Results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan. Reprod Health. 2020;17(1):1–9.
Awoleke JO, Adeyanju BT, Adeniyi A, Aduloju OP, Olofinbiyi BA. Randomised Controlled Trial of Sublingual and Rectal Misoprostol in the Prevention of Primary Postpartum Haemorrhage in a Resource-Limited Community. J Obstet Gynecol India
Lang DL, Zhao FL, Robertson J. Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings. BMC Pregnancy Childbirth
Tiruneh GT, Yakob B, Ayele WM, Yigzaw M, Roro MA, Medhanyi AA, et al. Effect of community-based distribution of misoprostol on facility delivery: A scoping review. BMC Pregnancy Childbirth. 2019;19(1).
Hobday K, Zwi AB, Homer C, Kirkham R, Hulme J, Wate PZ, et al. Misoprostol for the prevention of post-partum haemorrhage in Mozambique: An analysis of the interface between human rights, maternal health and development. BMC Int Health Hum Rights. 2020;20(1):1–13.
Diop A, Daff B, Sow M, Blum J, Diagne M, Sloan NL, et al. Oxytocin via Uniject (a prefilled single-use injection) versus oral misoprostol for prevention of postpartum haemorrhage at the community level: A cluster-randomised controlled trial. Lancet Glob Heal [Internet]. 2016;4(1):e37–44.
Yadav S, Malhotra A. A prospective randomized comparative study of Misoprostol and balloon tamponade using condom catheter to prevent postpartum hemorrhage at M. Y. H., Indore, India in vaginal delivered patients. Int J Reprod Contraception, Obstet Gynecol. 2019;8(2):591.
Smith JM, Baawo SD, Subah M, Sirtor-Gbassie V, Howe CJ, Ishola G, et al. Advance distribution of misoprostol for prevention of postpartum hemorrhage (PPH) at home births in two districts of Liberia. BMC Pregnancy Childbirth. 2014;14(1):1–10.
Samnani AABA, Rizvi N, Ali TS, Abrejo F. Barriers or gaps in implementation of misoprostol use for post-abortion care and post-partum hemorrhage prevention in developing countries: A systematic review. Reprod Health. 2017;14(1):1–10.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
